SCHEMBL29943231

SCHEMBL29943231

COC(=O)c1ccc(CN2CCN(C(=O)OC(C)(C)C)CC2)cc1C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GLS O94925 2/20 0.47
VEGFA P15692 1/20 0.47
EGLN1 Q9GZT9 1/20 0.47
NR1H2 P55055 1/20 0.46
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
IDO2 Q6ZQW0 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
TBK1 Q9UHD2 4/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23301852 1.00 ALDH1A1 (0.49) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL25487258 0.91 ALDH1A1 (0.53) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL28662739 0.90 FAAH (0.49) ALDH1A1NPSR1KDM4EVEGFAEGLN1
SCHEMBL29190915 0.90 FAAH (0.47) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL20567152 0.88 FAAH (0.48) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL20567000 0.88 ALDH1A1 (0.45) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL25978382 0.87 VEGFA (0.47) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL29942743 0.85 IDO1 (0.48) KDM4EGLSVEGFAEGLN1IDO1
Hydrochloric Acid SCHEMBL23301521 0.84 IDO1 (0.48) ALDH1A1NPSR1KDM4EGLSVEGFA
SCHEMBL30834656 0.84 VEGFA (0.52) ALDH1A1NPSR1KDM4EVEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051674-A1 BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2022-09-07 EP disclosed